Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Blood (2025) 146 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2025-4523

Published: 2025

Journal Articles

Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

Neela Easwar, Mia Andreoli, Herman Van Besien, Caitlin Gribbin, Michelle Pasciolla, Anna Alperovich, Mateo Mejia-Saldarriaga, Barbara Ma, Nora Chokr, Amer Assal, Joshua Fein, Sebastian Mayer, Alexandra Gomez-Arteaga, Daniel Choi, Tsiporah Shore, Christopher Hackett, Juliet Barker, Samuel Yamshon

Blood (2025) 146 (Supplement 1): 712.

https://doi.org/10.1182/blood-2025-712

Published: 2025

Journal Articles

A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas

Samuel Yamshon, Caitlin Gribbin, Yusuke Isshiki, Ioannis Karagiannidis, Sunjae Lee, Jizhi Yan, Gwynne Ozkan, Anna Alperovich, Barbara Ma, Christopher Hackett, Mateo Mejia-Saldarriaga, Daniel Choi, Selina Chen-Kiang, John Leonard, Ari Melnick, Juliet Barker, Giorgio Inghirami, Wendy Béguelin, Peter Martin

Blood (2025) 146 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2025-1011

Published: 2025

Journal Articles

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Jia Ruan, David A. Bond, Bijal D Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Brittany Hobbie, Melinda Harbhajan, Tejasvi Sahni, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen-Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 746.

https://doi.org/10.1182/blood-2024-204495

Published: 2024

Journal Articles

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2024-194601

Published: 2024

Journal Articles

Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Blood (2024) 144 (Supplement 1): 229.

https://doi.org/10.1182/blood-2024-204606

Published: 2024

Journal Articles

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Blood (2024) 144 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2024-194681

Published: 2024

Journal Articles

Leveraging SMARCA4 Dependency of Mantle Cell Lymphomas to Overcome BTK Inhibitor Resistance

Soo Yeon Hwang, Helgi Nikoli, Selina Chen-Kiang, Caitlin Gribbin, Peter Martin, Jihye Paik

Blood (2024) 144 (Supplement 1): 1364.

https://doi.org/10.1182/blood-2024-212104

Published: 2024

Journal Articles

Follicular Dendritic Cells Represent a Therapeutic Vulnerability in Early Follicular Lymphoma

Caitlin Gribbin, Dylan McNally, Ioannis Karagiannidis, Henna S. Nam, Hiranmayi Ravichandran, Baptiste Brauge, Karin Tarte, Amy Chadburn, Madhu M Ouseph, Sebastian Carrasco, Christian Steidl, David W. Scott, Ari M Melnick, Wendy Béguelin

Blood (2024) 144 (Supplement 1): 739.

https://doi.org/10.1182/blood-2024-198542

Published: 2024

Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan

Blood (2023) 142 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2023-178231

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Racial and socioeconomic disparities in clinical trial participation and outcomes in systemic peripheral T-cell lymphoma (PTCL): A multicenter retrospective Study

Real-world assessment of prophylactic anakinra on neurotoxicity after CD19 CAR T-cell therapy in R/R B-cell lymphoma: An inverse probability of treatment weighting analysis

A phase 1b trial of the EZH2 inhibitor tazemetostat combined with CAR T cell therapy in B cell lymphomas

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Real World First-Line Treatment Strategies and Outcomes in TP53 Mutated and Unmutated Mantle Cell Lymphoma

Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes

Subsets of Follicular Lymphoma (FL) 3B Have Divergent Biological Behavior and Clinical Outcome: Results from the Prospective Multicenter MER and LEO Cohorts

Leveraging SMARCA4 Dependency of Mantle Cell Lymphomas to Overcome BTK Inhibitor Resistance

Follicular Dendritic Cells Represent a Therapeutic Vulnerability in Early Follicular Lymphoma

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only